What are my options for losing weight? Where GLP-1 medicines fit
Food and activity, older weight-loss medicines, GLP-1 medicines, balloons and surgery, side by side, with the Australian criteria and who pays.
There are five main routes:
- Lifestyle changesFood, activity and support. The base for all the others.
- Older weight-loss medicinesOrlistat, phentermine or naltrexone–bupropion. They help a little to a moderate amount.
- GLP-1 medicinesSuch as semaglutide (Wegovy) and tirzepatide (Mounjaro)
- Endoscopic proceduresDone through the mouth, without cutting the skin
- Weight-loss surgeryThe largest, longest-lasting loss, but a major operation
They differ a lot in weight lost, risk and who pays. Medicines, procedures and surgery are added to lifestyle changes, not used instead of them. Procedures and surgery are only for much higher BMIs. Talk to your GP before starting, stopping or changing any treatment. See which are for you
Key facts
- Lifestyle programmes
- About 9% of body weight lost after 1 year in a large trial, 6% after 10 years1
- Older medicines
- Orlistat adds a few kilos of loss; naltrexone–bupropion about 5% more than a dummy pill2,33
- GLP-1 medicines
- About 15–21% lost in trials of people without diabetes. Weight returns after stopping.4,5,6
- Surgery
- The largest and longest-lasting loss: about 25% of body weight 10 years after a gastric bypass, with operation risks7,8
- Australian view
- Supervised lifestyle change is part of every weight-loss plan; medicines and surgery are added to it3
On this page
- Which options are for you?
- How do the options compare?
- Can food and activity changes alone help?
- What about pills, and other medicines that lower weight a little?
- Where do GLP-1 medicines fit?
- Who is weight-loss surgery for in Australia?
- What are gastric balloons and endoscopic sleeves?
- How do Australian doctors build up care?
- Questions people ask
Which options are for you?
It depends mostly on your BMI and your health. Lifestyle changes are for everyone. Medicines come in at a lower BMI. Procedures and surgery are for much higher weights.
So if your BMI is in the high 20s, the choice is usually between lifestyle changes alone and lifestyle changes plus a medicine. At 170 cm (5 ft 7 in), a BMI of 27 is about 78 kg (172 lb). Surgery usually starts around a BMI of 35 to 40, about 101 to 116 kg (223 to 256 lb) at the same height.3,9
The product information and the PBS are different things. The product information, approved by the TGA, says who a medicine is for: Wegovy and Mounjaro from a BMI of 30, or 27 with a condition such as high blood pressure.9,10 The PBS decides what the government subsidises, and no GLP-1 medicine is subsidised for weight. The PBAC has recommended Wegovy for some people with heart disease and a high BMI, but it hadn't been listed by July 2026.13,39
These are points where you and a doctor can start a conversation, not rules that you must or must not have something. The Australian algorithm also looks at your health, not just your weight.3
How do the options compare?
In trials, surgery led to the most weight loss. GLP-1 medicines came next, but only while people kept taking them. Lifestyle programmes and pills led to less.
The numbers below come from different trials, with different people. So treat them as rough guides. They are not a direct comparison. "Weight lost" is the average share of starting body weight.
- Dummy injection (for comparison)2–3 kg4,5
- Orlistat (capsule)~3 kg more than a dummy pill2
- Lifestyle programme~8 kg1
- Gastric balloon~9 kg11
- Endoscopic sleeve (ESG)~12 kg12
- GLP-1 medicine~13–19 kg4,5
- Gastric bypass surgery~23–29 kg7
Rough guide only: different trials, different people and different lengths of time. Details for each option are below.
Each option in detail. Weight lost is the average share of starting weight.
Lifestyle programme
OngoingA structured plan: a calorie target, regular activity, and regular sessions with a dietitian or coach. More ↓
Orlistat (capsule)
OngoingA capsule taken with meals that stops some of the fat you eat from being absorbed. More ↓
Over 4 years2
GLP-1 medicine
OngoingA weekly injection that makes you less hungry. Explained in Guide 2. More ↓
Gastric balloon
One-off, temporaryA soft balloon is put into your stomach through the mouth, so there's less room for food. It's taken out after about 6 months. More ↓
At 6 months, about 8% at 1 year11
Endoscopic sleeve (ESG)
One-offStitches are put inside your stomach through the mouth to make it smaller. No cuts in the skin. More ↓
At 1 year12
Weight-loss (bariatric) surgery
One-off, lifelong follow-upAn operation that makes your stomach much smaller. Some types, like gastric bypass, also reroute the gut so food skips part of it. More ↓
Gastric bypass: 32% at its peak (1–2 years), 25% at 10 years7
We don't show prices in Australia. Pharmacies and clinics set their own, and medicine costs repeat every month. Your pharmacist can tell you what a script costs, and your GP and health fund what a procedure costs.
In the medicine trials, the dummy-injection groups lost 2.4% and 3.1%, or about 2–3 kg.4,5 These are averages, and results vary from person to person. In those trials, about 14 in 100 people on semaglutide and 9 in 100 on tirzepatide lost less than 5% of their weight.4,5
Can food and activity changes alone help?
Yes, for many people. Structured programmes helped people lose around 6–9% of their weight, and cut their risk of diabetes.
One large trial, Look AHEAD, followed 5,145 adults with type 2 diabetes.1 The programme set a calorie target and about 3 hours of activity a week, with frequent group and one-to-one sessions.1 People lost 8.6% of their weight in the first year, against 0.7% with usual care.1 After about 10 years, they were still 6.0% lighter, against 3.5%.1
In the US Diabetes Prevention Program, 3,234 people with high blood sugar (prediabetes) took part.25 The lifestyle group lost 5.6 kg (about 12 lb) on average over about 3 years, against 0.1 kg on a dummy pill.25 Their rate of new diabetes was 58% lower: 4.8 cases per 100 people a year, against 11.0.25
Food: how much to cut
The Australian algorithm describes three steps of eating less:3
- Reduced energy diet: about 2,000–4,000 kJ (480–960 Calories) a day less than you need, mostly by eating vegetables, fruit, wholegrains, legumes, lean protein and dairy, and fewer "discretionary" foods like sweets, chips and sugary drinks.
- Low energy diet: 4,200–5,000 kJ (1,000–1,200 Calories) a day in total, with a set meal plan or one or two meal replacements.
- Very low energy diet: under 3,300 kJ (800 Calories) a day using meal-replacement shakes, with at least monthly check-ups. It's often used for up to 12 weeks, and it isn't for everyone: for example not in pregnancy, and with care over 65.
Protein: the part most people miss
When you lose weight, some of it is muscle. Too little protein makes that worse, and a smaller appetite on a GLP-1 medicine makes protein harder to get.27
- 0.8 g per kg of body weight is the usual minimum for adults.
- 1.2–1.6 g per kg has been proposed while you're losing weight.
- Don't go below 0.4–0.5 g per kg, which leads to muscle loss, or stay at 2 g per kg or more for long.27
The same advisory says to pair protein with strength exercise at least 3 times a week, plus at least 150 minutes of moderate activity like brisk walking.27 If you have kidney disease, ask your doctor before raising your protein.
What to put on the plate
The Australian Dietary Guidelines suggest eating a wide variety of foods from five groups every day. You don't need every group at every meal.16
Activity and support
Activity. Australia's guidelines advise adults aged 18 to 64 to do 150 to 300 minutes of moderate activity a week, like brisk walking, or 75 to 150 minutes of vigorous activity, like running, plus muscle-strengthening activities on at least 2 days.15 For people on a GLP-1 medicine, the US advisory above suggests strength exercise at least 3 times a week.27 The Australian algorithm says resistance exercise helps protect muscle, and people with joint, heart or lung problems may need a gentler or water-based plan, perhaps with an exercise physiologist.3 Speak to your GP first if you haven't exercised for a while or have a medical condition.
Support. The Australian algorithm treats supervised lifestyle support as part of every plan, including when a medicine is used.3 WHO also says diet and activity programmes may be offered alongside GLP-1 medicines.30
What about pills, and other medicines that lower weight a little?
Before GLP-1s, Australia approved three other medicines for weight. They help a little to a moderate amount. Some diabetes medicines also lower weight a little.3
Orlistat (Xenical) stops about 30% of the fat in your food from being absorbed; it passes out in your poo. Oily spotting, fatty stools and wind are common if you eat more than about 30 g of fat a day. Over time it can lower vitamins A, D, E and K.3 In a 4-year trial, people on orlistat lost 5.8 kg, against 3.0 kg on a dummy pill.2
Phentermine (sold as Duromine, Metermine and others) is an appetite suppressant approved for short-term use, 3 months, alongside diet. It can raise heart rate and blood pressure and cause sleeplessness and a dry mouth, so it isn't for people with heart disease, an irregular heartbeat or uncontrolled blood pressure, or with some antidepressants.3
Naltrexone–bupropion (Contrave) is a combination tablet for weight. In a 56-week trial, people lost 6.1% of their weight, against 1.3% on a dummy pill. Feeling sick and vomiting are the main side effects.3,33
Metformin is a diabetes medicine, not an approved weight-loss one. In the Diabetes Prevention Program it led to 2.1 kg of loss on average.25 An international PCOS guideline says doctors should consider it for women with PCOS (polycystic ovary syndrome) and a BMI of 25 or more.31
SGLT2 inhibitors, such as dapagliflozin, lead to modest weight loss. Across 116 trials, people lost about 1.8 kg more than on a dummy pill.32
Where do GLP-1 medicines fit?
They lead to more weight loss than pills or lifestyle alone. But they are a long-term treatment, and most of the weight returns if you stop.
Semaglutide (Wegovy) acts like the gut hormone GLP-1.20 Tirzepatide (Mounjaro) acts on GLP-1 and a second gut hormone, GIP.5 Guide 2 explains how they work. In every trial below, people also followed a diet and activity plan.4,5
Average weight lost in each trial. Kilograms are for someone who starts at 90 kg (198 lb).
Adults without diabetes, 68 weeks.4
Adults without diabetes, 72 weeks.5
Adults with type 2 diabetes, 68 weeks.20
The only trial that compared them directly, 72 weeks. Paid for by the maker of tirzepatide.35
Only the last trial compared the two medicines directly; the others each tested one medicine against a dummy injection, so don't compare across them.
Checking it's working. The Australian algorithm sets a target of 10–15% weight loss for many people, and says to step up or change the plan if targets aren't met.3 For teenagers on Wegovy, the product information says to stop if BMI hasn't fallen by 5% after 12 weeks on the full dose.9
Tablets. We found no GLP-1 tablet approved for weight in Australia as of October 2026. The trial results on this page are for weekly injections.4,5
What happens when you stop. A year after stopping semaglutide, trial participants had regained about two-thirds of the weight they lost.6 In a tirzepatide trial, everyone first took the medicine for 36 weeks and lost about 21% of their weight.37 Then some were switched to dummy injections. Over the next year, their weight went up by 14% of what they weighed at the switch.37 For someone who weighed 85 kg (187 lb) by then, that is about 12 kg (85 × 0.14 = 11.9). Those who stayed on tirzepatide lost a further 5.5% over the same year.37 The Australian algorithm says weight-loss medicines will usually be needed long term.3 Guide 9 covers stopping.
Who pays. No GLP-1 medicine is on the PBS for weight, so for weight you pay the full price on a private script, every month you take it.13 Mounjaro's maker turned down the price terms for a PBS listing in 2026.19 Some private health extras policies pay part of a non-PBS script, within limits; others exclude weight-loss medicines.18,40 For type 2 diabetes, Ozempic and Trulicity are on the PBS if you meet the criteria, and you pay the PBS co-payment.17,38 Ask your pharmacist what your script will cost. Guide 6 covers who pays and safe ways to get them.
Who it's for. The product information allows Wegovy and Mounjaro for weight from a BMI of 30, or 27 with a weight-related condition.9,10 That is a point where you and a doctor can start talking about it. It does not mean you should take one. Guide 4 covers who should and shouldn't take them.
Who is weight-loss surgery for in Australia?
Surgery is for people with a higher BMI, often with a health condition that weight loss could improve. It gives the largest, longest-lasting loss, but it is a major operation.
Australian thresholds
The Australian algorithm quotes the national criteria from 2013 (that guideline has since been rescinded, and a new one wasn't final when we checked). Taking your situation into account, surgery may be considered for adults with:3,42
- a BMI over 40, or
- a BMI of 35 to 39.9 with health conditions that may improve with weight loss, or
- a BMI of 30 to 34.9 with poorly controlled type 2 diabetes and a higher risk of heart disease.3
For type 2 diabetes, the Australian Diabetes Society backs surgery from a BMI of 40 whatever your sugar control, from 35 if sugar stays high despite treatment, and says to consider it from 30.3 For Asian people, and as recommended for Aboriginal and Torres Strait Islander people, the algorithm moves its BMI groups down by 2.5.3 Newer guidance from US and international surgeons (2022) offers surgery from a BMI of 35, or 27.5 for Asian people.8 The algorithm says surgery should be part of care from a team, with long-term follow-up.3
Results
A Swedish study followed over 4,000 people. Gastric bypass led to 32% loss at its peak, and 25% after 10 years.7 Gastric banding, which puts a band around the stomach, led to less: 20% and 14%.7 People who had surgery were less likely to die during the study than similar people who didn't.7
Diabetes. In a US trial, 5 years after surgery, 29 in 100 (bypass) and 23 in 100 (sleeve) had near-normal blood sugar.41 With medicines alone, it was 5 in 100.41 In a Finnish trial, about 1 in 4 to 1 in 3 had diabetes in remission at 10 years.22
Risks
- Death around the time of the operation is rare: between 3 in 10,000 and 2 in 1,000.8
- Over 10 years, 16–19 in 100 needed another operation.22
- Acid damage to the food pipe was found in 31 in 100 after a sleeve, against 7 in 100 after a bypass.22
- The Australian algorithm says people who have had surgery need long-term follow-up, and GP practices should keep them in regular review.3
Who pays. Ask your GP about public hospital options where you live, and your health fund about what your cover includes.
What are gastric balloons and endoscopic sleeves?
Both are done through the mouth with a camera tube (an endoscope), without cutting the skin.11,12 Neither removes any part of the stomach.11,12
Gastric balloon. A balloon is placed in the stomach using the endoscope. In a US trial, it was removed after 6 months.11 People lost 10.2% of their weight by then, against 3.3% with lifestyle alone.11 By 12 months, loss had eased to 7.6%.11 Feeling sick (87 in 100) and vomiting (76 in 100) were common, and 19 in 100 had it taken out early.11 The trial included adults with a BMI of 30 to 40.11
Endoscopic sleeve gastroplasty (ESG) reshapes the stomach from the inside.12 In a trial at nine US centres, adults with a BMI of about 30 to 40 (class 1 or 2 obesity) took part.12 They lost 13.6% at 1 year, against 0.8% with lifestyle alone.12 Serious problems happened in 2 in 100 people.12
How do Australian doctors build up care?
There is no single fixed order. The Australian algorithm sets the plan by your BMI, your waist and any weight-related health problems, and diet and activity stay part of every plan.3
Your GP usually leads, and shares care with specialists for people with a higher BMI or health problems. People with a BMI over 40 and complications are best looked after by a specialist team.3 Here is a simple picture of how the options fit:
- 1Food, activity and supportThe base for everyone, at every step above, from a reduced energy diet up to a very low energy diet with meal replacements3
- 2Adding a medicineUsually from your GP, added to a diet plan when diet and activity alone haven't been enough3
- 3
- 4Bariatric surgeryAssessed by a surgical team. Mainly from a BMI of 40, or 35 with a related condition3
For example, the algorithm says a very low energy diet can be used before surgery, and medicines can help keep weight off after a diet or prevent regain.3
Questions people ask
Can I just diet instead?
Yes. Changing what you eat and how much you move can work on its own, with no medicine, no procedure and none of their side effects. For many people it's enough, and it's the base of every other plan. The evidence for it is strong:
- It prevents diabetes. In large trials, structured programmes led to 6–9% weight loss on average and far fewer new cases of diabetes: 58% fewer in the US trial.1,25
- Big results are possible. In a trial in Scotland and England called DiRECT, people with type 2 diabetes stopped their diabetes medicines and followed a diet plan: a few months of low-calorie meal-replacement shakes, then a slow return to normal food, with support. After a year, 1 in 4 had lost 15 kg (33 lb) or more, and almost half no longer had diabetes. Among those who lost 15 kg or more, 86 in 100 were free of it.26
- People do keep it off. About 1 in 5 people with overweight manage to lose 10% of their weight and keep it off for at least a year. A US registry of people who succeeded has members who lost an average of 33 kg (73 lb) and kept it off for more than 5 years.43
What the people who keep it off have in common: about an hour of activity a day, a lower-calorie diet, eating breakfast, weighing themselves regularly, and eating the same way on weekdays and weekends.43
Not everyone gets these best results: trial averages are smaller, and some weight often creeps back over the years.1 If diet and activity alone don't get you far enough, medicines are added on top, not used instead.3
Is surgery safer than lifelong injections?
They're usually for different people. In Australia, surgery is mainly for a BMI over 40, or over 35 with a related condition.3 GLP-1 medicines are approved for weight from a BMI of 30, or 27 with a weight-related condition.9 So at a BMI in the high 20s, surgery usually isn't on the table. Where both are options, they carry different risks. Surgery has a small risk of death at the time, and some people need a second operation.8,22 GLP-1 medicines have ongoing side effects, and most of the weight returns if you stop.6,21 A medicine for weight is paid for every month you take it, with no PBS subsidy.13
Do herbal or "natural" slimming products work?
The Australian algorithm lists no herbal product among weight-loss medicines.3 In the US, many slimming products sold as supplements or "all-natural" have been found to contain hidden drugs.34 In Australia, "GLP-1" drops and patches sold online contained no GLP-1 medicine when the TGA tested them.23
Can I take metformin to lose weight?
Metformin isn't a weight-loss medicine. In a large trial, it led to about 2 kg of loss.25 Doctors use it for type 2 diabetes, and for some women with PCOS.31
If I take a GLP-1, do I still need to change what I eat?
Yes. Wegovy and Mounjaro are approved as an add-on to a reduced-calorie diet and more physical activity.9,10 A 2026 Australian heart consensus says these medicines complement behaviour change rather than replace it.29 WHO also says diet and activity support should go alongside them.30
Before you move on
- Lifestyle changes are the base of every option, including medicines and surgery.
- Older weight-loss medicines, like orlistat, help a little to a moderate amount.
- GLP-1 medicines lead to more loss, but weight returns on stopping. There's no PBS subsidy for weight.
- Surgery gives the most lasting loss, but it's a major operation with lifelong follow-up.
- There's no fixed order. A doctor matches the option to you.
Sources
- Pi-Sunyer X. The Look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep, 2014. DOI · Full text
- Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 2004. DOI
- Markovic TP, Proietto J, Dixon JB et al. The Australian Obesity Management Algorithm. Australian Diabetes Society, with ANZOS, ANZMOSS and the RACGP, July 2024. diabetessociety.com.au
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021. DOI
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022. DOI
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab, 2022. DOI
- Sjöström L et al. Effects of bariatric surgery on mortality in Swedish obese subjects (SOS). NEJM, 2007. DOI
- Eisenberg D et al. 2022 ASMBS and IFSO indications for metabolic and bariatric surgery. Obes Surg, 2023. DOI · Full text
- Novo Nordisk. Wegovy (semaglutide) Australian Product Information, revised 22 June 2026 (sections 4.1, 4.2, 4.4, 4.6, 4.8, 6.4). medsinfo.com.au
- Eli Lilly. Mounjaro (tirzepatide) Australian Product Information, version A14.0, October 2026 (sections 4.1, 4.5, 4.6, 6.4). medsinfo.com.au
- Courcoulas A et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes, 2017. DOI
- Abu Dayyeh BK et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT). Lancet, 2022. DOI
- Pharmaceutical Benefits Scheme. Medicine status: semaglutide (Wegovy), document 1460 ("Medicine listed on PBS: Has not yet occurred"), updated 23 July 2026. pbs.gov.au
- Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity, 2014;22(1):5–13 (26.9% of the lifestyle group had lost 10% or more at year 8). DOI
- Department of Health, Disability and Ageing. Physical activity and sedentary behaviour guidelines for adults (18 to 64 years), fact sheet: 150 to 300 minutes of moderate or 75 to 150 minutes of vigorous activity a week, plus muscle-strengthening activities on at least 2 days. health.gov.au
- National Health and Medical Research Council. Australian Dietary Guidelines, Guideline 2: the five food groups. Eat for Health. eatforhealth.gov.au
- Pharmaceutical Benefits Scheme. Type 2 diabetes mellitus pharmacotherapy diagram, at 1 December 2024 (GLP-1 RA subsidised after an SGLT2 inhibitor is contraindicated, not tolerated or not effective, with HbA1c above 7% on metformin, a sulfonylurea or insulin). pbs.gov.au
- HIF. Can you claim for weight loss drugs on your extras cover? ("Benefits can only be paid on non-PBS prescription items"; "The cost of the item must exceed the current PBS co-payment"). 30 July 2026. Insurer article. hif.com.au
- newsGP (RACGP). Mounjaro manufacturer rejects PBS recommendation ("price conditions proposed by the Australian Government are unrealistic and unviable"). 28 April 2026. racgp.org.au
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet, 2021. DOI
- Novo Nordisk. Wegovy (semaglutide) prescribing information, US label (FDA), revised June 2026: warnings on pancreatitis, gallbladder disease, acute kidney injury and thyroid C-cell tumours. Not the Australian label. DailyMed
- Salminen P et al. Sleeve gastrectomy vs Roux-en-Y gastric bypass at 10 years (SLEEVEPASS). JAMA Surg, 2022. DOI
- Therapeutic Goods Administration. Counterfeit weight loss products claiming to contain GLP-1 (laboratory testing found "no GLP-1 or any GLP-1 analogues"). Safety advisory, 2 March 2026. tga.gov.au
- Therapeutic Goods Administration. Imported unregistered GLP-1 weight loss products (oral "GLP-1 peptide" drops with fake endorsements). Safety advisory, 29 September 2025. tga.gov.au
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM, 2002. DOI · Full text
- Lean MEJ, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, 2018;391(10120):541–551. 306 people in Scotland and England. DOI
- Mozaffarian D, Agarwal M, Aggarwal M et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122(1):344–367. DOI · PMC12612741
- Therapeutic Goods Administration. Update: glucagon-like peptide-1 receptor agonists (GLP-1 RAs) pharmacy compounding changes (no compounding of any GLP-1 RA from 1 October 2024). Media release, 18 June 2024. tga.gov.au
- newsGP (RACGP). Critical role of GLP-1s addressed in Australian-first consensus (Heart Foundation statement: incretin medicines "complement, not replace" behaviour change). 18 May 2026. racgp.org.au
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. News release, 1 December 2025. WHO
- Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril, 2023. Declared interests: 1 of 13 named authors declares speaker fees from Novo Nordisk (paper's own declaration). DOI
- Cheong AJY et al. SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials. Obesity, 2022. DOI
- Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet, 2010;376:595–605. doi:10.1016/S0140-6736(10)60888-4
- US Food and Drug Administration. Weight loss product notifications (medication health fraud). Updated 4 September 2026. FDA
- Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM, 2025. DOI
- Therapeutic Goods Administration. Reporting adverse events: consumers (report online, or ask your doctor or pharmacist to report). Updated 2 September 2026. tga.gov.au
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024. DOI
- Pharmaceutical Benefits Scheme. What are the current patient fees and charges? (the co-payment set from 1 January 2026, lower with a concession card, and the safety net). pbs.gov.au
- newsGP (RACGP). Wegovy recommended for PBS listing (established cardiovascular disease; BMI 35 or more, or 32.5 or more for Asian, Aboriginal or Torres Strait Islander patients). 19 December 2025. racgp.org.au
- The Nightly. Private health insurer HBF tightens belt on weight-loss drug coverage (Saxenda, Contrave, Duromine, Wegovy and compounded weight-loss medicines dropped from 9 July 2024). 1 May 2024. News report. thenightly.com.au
- Schauer PR et al. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes (STAMPEDE). NEJM, 2017. DOI
- National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity (2013 edition, "Rescinded"); Department of Health, Disability and Ageing public consultation on new guidelines, closed 16 December 2024. nhmrc.gov.au
- Wing RR, Phelan S. Long-term weight loss maintenance. American Journal of Clinical Nutrition, 2005;82(1 Suppl):222S–225S. Registry members volunteer, so they are not a random sample. DOI
Last checked 12 Oct 2026 · Next review due Jan 2027 · Report an error
How this guide was made. Written by the GLP Guidebook team from the sources above: Australian guidance and product information, TGA and PBS documents, and published trials. We don't list or compare prices. It's general information, not medical advice. Talk to your GP or another qualified prescriber before starting, stopping or changing any medicine. In an emergency, call triple zero (000). For health advice any time, call healthdirect on 1800 022 222. Report suspected side effects to the TGA. How we write